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Abstract: A large number of preclinical studies suggest the involvement of resveratrol in the
prevention and treatment of eye diseases induced by oxidative stress and inflammation. We tested
the hypothesis that resveratrol influences many pathways of in vitro and in vivo models of diabetic
retinopathy through a systematic literature review of original articles. The review was conducted
in accordance with the PRISMA guidelines. A literature search of all original articles published
until April 2019 was performed. The terms “resveratrol” in combination with “retina”, “retinal
pathology”, “diabetic retinopathy” and “eye” were searched. Possible biases were identified with
the adopted SYRCLE’s tool. Eighteen articles met inclusion/exclusion criteria for full-text review.
Eleven of them included in vitro experiments, 11 studies reported in vivo data and 3 studies described
both in vitro and in vivo experiments. Most of the in vivo studies did not include data that would
allow exclusion of bias risks, according to SYRCLE’s risk of bias tool. Both in vitro and in vivo
data suggest anti-apoptotic, anti-inflammatory and anti-oxidative actions of resveratrol in models of
diabetic retinopathy. However, results on its anti-angiogenic effects are contradictory and need more
rigorous studies.
Keywords: 3,4’,5-trihydroxystilbene; eye; diabetic retinopathy; neovascularization; polyphenol;
resveratrol; retina
1. Introduction
Resveratrol, known also as 3,4’,5-trihydroxystilbene, is a natural polyphenol that is present in
various fruits and vegetable and mainly found in grapes, leading to its high concentration in wines [1].
Peanuts, blueberries, bilberries and cranberries are other available sources [2,3].
The concentrations of resveratrol in red wine change from 8–25 µM, depending on the types of
grapes used and their culture conditions [3]. The seeds and skin of grapes are rich in resveratrol, but it
has relatively poor solubility in water. On the contrary, resveratrol is soluble in low percentages of
alcohol, and so it is effectively absorbed by the body from wine [4].
Resveratrol is made up of two aromatic rings connected by a methylene bridge [5]. There are
two different structures of resveratrol: cis- and trans-resveratrol [5]. The cis-isomeric form had not
been located in grapes, but it has been known that trans-resveratrol can become cis after isomerization
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when exposed to ultraviolet irradiation [6]. Jeandet et al. showed that wine may hold high amounts of
the cis-isomer if it was produced in the dark without the presence of light [7].
The literature has reported beneficial effects of resveratrol on the human body [1]. It exhibits
a wide range of biological activities, including neuro- and cardioprotection, anti-aging, anti-cancer
and anti-diabetic effects [8]. Resveratrol is thought to act mainly through modulation of oxidative
stress, but also by modulating other physiological processes like inflammation, cell proliferation and
apoptosis or angiogenesis [8]. Moreover, several studies have highlighted the effects of resveratrol
within the eye as an anti-oxidant, anti-apoptotic, anti-tumor, anti-inflammatory, antiangiogenic and
vasorelaxant molecule.
A recent review by Singh et al. [9] on clinical trials including resveratrol identified 244 finished
registered clinical trials, and 27 ongoing clinical trials. The published results suggest that resveratrol
improved some clinical outcomes in patients suffering from numerous diseases, including obesity,
malignancies (colorectal cancer and breast cancer), hypertension, Alzheimer’s disease, stroke,
cardiovascular diseases and diabetes. Moreover, the clinical data suggest that resveratrol is safe
even at high doses: administration of micronized resveratrol (SRT501) in cancer patients led to no
serious side effects [10].
There is evidence that oxidative stress and inflammation promote the initiation and progression of
age-related ocular diseases, including diabetic retinopathy (DR), which leads to progressive blindness
if untreated [11–13]. Regarding these considerations, it has been proposed that anti-oxidative and
anti-inflammatory phytochemicals may have a therapeutic potential in age-related ocular disorders [14].
Therefore, among phytochemicals, it has been shown that resveratrol could prevent the progression
of degenerative ocular diseases, responsible for severe sight loss [15].
DR is the most common cause of vision loss among working-age people, and it is defined as a
diabetes-induced microangiopathy affecting the retinal vasculature [15]. This is due to poor metabolic
control of circulating high blood glucose levels that leads to increased inflammatory response, ischemia
and cell degeneration resulting in malfunction of the blood–retinal barrier and loss of vision [16].
Resveratrol seems to control glucose metabolism, decrease insulin resistance and help to prevent
heart disorders, lipoprotein oxidation, apoptosis and inhibition of platelet aggregation [17]; it was
suggested to be an important factor in DR. Moreover, resveratrol has been proposed in the prevention
and treatment of diabetic complications [18]. However, to our knowledge, resveratrol potential in DR
was not evaluated in clinical trials.
Based on these premises, it is possible to hypothesize that some of the main biological activities of
resveratrol, its effects and plausible mechanisms of action as demonstrated in different in vitro and
in vivo conditions could influence the eye and play a role in pathologies such as DR.
The aim of the current systematic review was to summarize the available data in the literature
about the effect of resveratrol on in vitro and in vivo models of DR.
2. Results
From a total of 328 articles extracted from the initial research, there were 170 abstracts identified
for screening, and 18 of these met inclusion/exclusion criteria for full-text review. We excluded 13
articles: 7 review papers and 6 because of severe bias, i.e., other ocular diseases different from DR. Our
results are summarized in Figure 1.
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Figure 1. PRISMA 2009 flow diagram of the included studies. 
2.1. In Vitro Experiments 
Most of the in vitro studies were performed on culture of human retinal pigment epithelial cells 
ARPE-19 (4 out of 11 studies), and one study was performed on human retinal endothelial cells 
(hRECs). One study covered non-retinal cells, i.e. peripheral blood mononuclear cells (PBMCs) 
isolated from proliferative DR patients [19]. All the studies using animal cells were performed on 
primary cultures of retinal cells: primary culture of rat Müller cells (2 studies), bovine retinal capillary 
endothelial cells (BRECs; 2 studies) and rat retinal endothelial cells (RREC; 1 study). Only 3 out of 11 
studies provided data on identification of the cells and none of the articles using established ARPE-
19 cell line provided any information on preventing misidentification. 
DR was mimicked by culturing in high glucose conditions (25–33 mM glucose; 7 studies; in one 
of these studies additionally H2O2 exposure), exposure to PDGF-BB (20 ng/mL, 1 study) or CoCl2 
(100–1000 µM, 1 study). In one study, there was no diabetic retinopathy-mimicking treatment [19]. 
The tested resveratrol concentrations were in a range from 1 µM to 10 mM. However, in only two 
studies from the same research group did the tested resveratrol concentrations exceed 1 mM [20,21]. 
In vitro studies on resveratrol effect in animal models of DR are summarized in Table 1. 
Figure 1. PRISMA 2009 flow diagram of the included studies.
Eleven out of the 18 studies covered in this systematic review included in vitro experiments on
human or animal cells, 11 studies included in vivo data and 3 studies described both in vitro and
in vivo experiments.
2.1. In Vitro Experiments
Most of the in vitro studies were performed on culture of human retinal pigment epithelial cells
ARPE-19 (4 out of 11 studies), and one study was performed on human retinal endothelial cells (hRECs).
One study covered non-retinal cells, i.e. peripheral blood mononuclear cells (PBMCs) isolated from
proliferative DR patients [19]. All the studies using animal cells were performed on primary cultures
of retinal cells: primary culture of rat Müller cells (2 studies), bovine retinal capillary endothelial cells
(BRECs; 2 studies) and rat retinal endothelial cells (RREC; 1 study). Only 3 out of 11 studies provided
data on identification of the cells and none of the articles using established ARPE-19 cell line provided
any information on preventing misidentification.
DR was mimicked by culturing in high glucose conditions (25–33 mM glucose; 7 studies; in one
of these studies additionally H2O2 exposure), exposure to PDGF-BB (20 ng/mL, 1 study) or CoCl2
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(100–1000 µM, 1 study). In one study, there was no diabetic retinopathy-mimicking treatment [19]. The
tested resveratrol concentrations were in a range from 1 µM to 10 mM. However, in only two studies
from the same research group did the tested resveratrol concentrations exceed 1 mM [20,21]. In vitro
studies on resveratrol effect in animal models of DR are summarized in Table 1.
2.1.1. Resveratrol Effect on Cell Viability and Apoptosis
Chen et al. [22] showed that incubation of rat retinal endothelial cells (RREC) with resveratrol
in normal glucose conditions did not affect cell viability up to concentration of 100 µM resveratrol.
Lower resveratrol concentration suppressed high glucose-induced apoptosis (upregulation of active
caspase-3). Zeng et al. [20] demonstrated that resveratrol prevented high glucose-induced retinal
Müller cells apoptosis via microRNA-29b (miR-29b). Bax and specificity protein 1 (SP1) expression
was downregulated by resveratrol, while Bcl-2 was upregulated. miR-29b inhibitor reversed the
anti-apoptotic effect of resveratrol.
2.1.2. Resveratrol Effect on ROS Production/Oxidative Stress
Chang et al. [23] demonstrated that resveratrol reduced oxidative stress in ARPE-19 cells that
was induced by exposure to CoCl2 (hypoxic mimetic treatment). Soufi et al. [24] also showed
down-regulation of high glucose-induced oxidative stress hRECs (Human Retinal Endothelial Cells)
by pterostilbene, a homologous derivative of resveratrol. Li et al. [25] showed reduction of high
glucose-induced intracellular ROS elevation through the activation of AMPK/Sirt1/PGC-1α pathway
and apoptosis suppression in bovine retinal capillary endothelial cells (BRECs).
2.1.3. Resveratrol Effect on Inflammatory Markers
One study by Losso et al. [26] on ARPE-19 cells showed inhibitory effect of resveratrol on
high-glucose induced elevation of pro-inflammatory factors: decreased GJIC, secretion of cytokines
IL-6 and IL-8, downregulation of Cx43, activation of TGF-β, PKCβ, and COX-2. Also, Soufi et al. [24]
showed downregulation of inflammatory markers in hRECs (Human Retinal Endothelial Cells).
2.1.4. Resveratrol Effect on VEGF
A single study by Subramani et al. [27] demonstrated downregulation of VEGFR-2 and its
activation, reduction of VEGF-A, and a decrease in the proliferation of cultured RPE cells.
2.1.5. Other Cellular Effects of Resveratrol
Chan et al. [28] demonstrated involvement of PDGFRb, PI3K/Akt and MAPK pathways in
resveratrol-driven cellular response to PDGF-BB-induced migration. Data by Chang et al. [23] CoCl2
(100–1000 µM) showed that resveratrol reduced hypoxia-induced secretion of HMGB1. Kowluru
et al. [29] demonstrated involvement of Sirt1 activity inhibition and prevention of increase in the
acetylation of p65, binding of p65 with MMP-9 promoter and activation of MMP-9. Sirt 1 involvement
in resveratrol protection was also reported by Li et al. [25] and Liu et al. [19]. Zeng et al. [21] showed that
resveratrol prevented high glucose-induced decrease of glutamate transporters (GLAST) expression
and decrease in glutamate uptake.
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Table 1. In vitro studies on resveratrol effect on cultured retinal cells.








Laboratory Techniques Major Findings
Chan Chi-Ming, 2013
(Taiwan, USA) [26]







No data PDGF-BB (20 ng/mL)
at 37 ◦C for 30 minutes
1, 3 or 10 µM ECIS migration assay,
MTT assay, dot binding






































Primary culture of rat
cells
No data High glucose
conditions (30 mM
glucose for 7 days)
10, 50, 100, 200 or
500 µM (24 h)
MTT assay, WB, RT PCR Incubation with
resveratrol did not affect
cell viability up to






PON1 as well as
suppression of active
caspase-3 upregulation
driven by culturing in
exposure to elevated
glucose levels.
Int. J. Mol. Sci. 2019, 20, 3503 6 of 16
Table 1. Cont.








Laboratory Techniques Major Findings








No data H2O2 exposure




25 µM IP, RT PCR, WB, enzyme







binding of p65 with
MMP-9 promoter and
activation of MMP-9.































No data No insult 10 µM (72 h) ELISA, WB, RT PCR IL-17 expression was
upregulated and SIRT1
expression levels were




Losso Jack, 2010 (USA)
[24]
ARPE-19 Human cell line (retinal
pigment epithelial cells)
obtained from ATCC
No data High glucose
conditions (33 mM
glucose)

















Int. J. Mol. Sci. 2019, 20, 3503 7 of 16
Table 1. Cont.


















No data High glucose
conditions (33 mM
























No data Bevacizumab (0.25
mg/ml for 2 h)
100 µM (48 h) Trypan blue assay, MTT
assay, FLICA, RT PCR,






















for at least 3 days)






















for at least 3 days)


















Int. J. Mol. Sci. 2019, 20, 3503 8 of 16
2.2. In Vivo Experiments
The analyzed animal studies were conducted on laboratory rodents: mice (C57Bl/6—3 studies; and
transgenic Nestin-Cre mice, Tie2-Cre mice—1 study) or rats (Wistar rats—4 studies; Sprague-Dawley—3
studies; Dark Agouti—1 study). Therefore, only 4 out of 11 studies were performed on pigmented
strains. In 10 out of 11 studies, DR was induced by injection of streptozotocin (mostly as a single
intraperitoneally or intravitreal injection in a dose ranging from 50 to 60 mg/kg body weight). In a
single study [30], a model of oxygen-induced retinopathy (neonatal mice were exposed to 75% oxygen
from P7 to P12) was used. Apart from one study [31], all the studies investigated changes present in
the whole retina (one of these studies referred to ‘eye tissues’ [32]). Resveratrol was administered by
oral route (9 studies, doses ranging from 5 to 400 mg/kg/day), intraperitoneally (1 study, 5 mg/kg/day)
or by intravitreal injection (5µL of 0.1 µg/mL or 1 µg/mL solution). Bias risk in the in vivo studies is
summarized in Table 2. In vivo studies on resveratrol effect in animal models of DR are summarized
in Table 3.
Table 2. Summary of risk of bias analysis in studies on resveratrol effect in animal models of diabetic
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Table 3. In vivo studies on resveratrol effect in animal models of diabetic retinopathy.
Author, Year
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2.2.1. Resveratrol Effect on Retinal Cell Apoptosis
Four studies demonstrated that resveratrol reduced STZ-induced retinal cell apoptosis [20,22,24,33].
Chen et al. [22] demonstrated that intravitreal injection of resveratrol (5 µl of 0.1 µg/mL or 1 µg/mL
solution) reduced retinal elevation of active caspase-3 after diabetes induced by streptozotocin
administration. Soufi et al. in their two compatible papers [24,33] showed that prolonged oral
administration of resveratrol (5/mg/kg/day for 4 months) reduced STZ-induced apoptosis (measured
with cell death detection ELISA kit) and partially protected against STZ-induced retinal disorganization.
Zeng et al. [20] also demonstrated that prolonged oral administration (in both tested doses of 5 and
10 mg/kg/day) of resveratrol inhibited STZ-induced apoptosis (measured with TUNEL staining) within
the inner nuclear layer.
2.2.2. Resveratrol Effect on Inflammatory Markers
Five of the analyzed papers reported anti-inflammatory effects of resveratrol administration. Chen
et al. [22] reported that intravitreal injection of resveratrol reduced STZ-induced upregulation of several
inflammatory factors (IL-1β, IL-6, TNFα, VEGF, IFN-γ and MCP-1) and reduced ox-LDL in the retina.
They postulated that inflammation suppression might be driven by increased expression and activity
of PON1. Kubota et al. [34] reported that resveratrol suppressed diabetes-induced upregulation of
NF-κB signaling by activating the AMPK pathway. Three papers from Soufi et al. [24,33,35] showed a
decrease in inflammation as a result of resveratrol administration: it prevented STZ-induced activation
of NF-κB and STZ-induced upregulation of pro-inflammatory mediators (TNF-α, IL-6 and COX-2).
2.2.3. Resveratrol Effect on Oxidative Stress
Two studies demonstrated attenuation of oxidative stress after resveratrol treatment in animal
models of DR. Chen et al. [22] demonstrated reduction in ox-LDL level. Soufi et al. [24] showed
normalization of lipid peroxidation index and oxidized to reduced glutathione ratio. They also showed
increase in retinal superoxide dismutase activity after resveratrol administration.
2.2.4. Resveratrol Effect on ERG Parameters
A single report provided functional evaluation of retinal function after treatment with resveratrol.
Zeng et al. [21] showed that resveratrol administration provided an attenuation of diabetes-induced
decreases in the amplitude of a-wave in rod response, a- and b-wave in cone and rod response or OP2
in oscillatory potentials. It also significantly repressed diabetes-induced delay in OP2 implicit times in
scotopic 3.0 OPS test.
2.2.5. Resveratrol Effect on Vasculature
One study by Michan et al. [30] on a model of oxygen-induced retinopathy described an increase
of vaso-obliteration and no significant differences in pathologic neovascularization (although there
was a trend toward suppressing). In this study, resveratrol did not show protective effects against the
development of retinopathy. Kim et al. [36] demonstrated that resveratrol blocked diabetes-induced
increase of VEGF expression. However, Yar et al. [32] did not detect significant changes of mRNA levels
of VEGF, MMP-9, and ACE genes associated with vascular remodeling after resveratrol treatment.
2.2.6. Other Effects or Mechanisms
Al-Hussaini et al. [31] reported normalization of diabetes-induced decreases in expressions of Lpl,
Rdh12, Aldh1a3, Cralbp1, Cralbp2 but not Lpl, Lrat, Rdh5, Rdh10, RPE65, Rlbp1, and Rbp1 genes.
Long-term (30 days) but not short term (14 days) supplementation upregulated transcription of key
retinoic acid metabolism pathway enzymes. Kubota et al. [34] showed recovery of SIRT1 activity and
Zeng et al. [21] reported resveratrol-induced upregulation of glutamate transporters (GLAST) and
glutamine synthetase (GS) in the retina.
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3. Discussion
DR is a priority eye disease on the VISION 2020 list, for prevention and treatment. Despite
laser photocoagulation, intravitreal drugs and vitreoretinal surgery are the standard treatment care,
the vision-threatening condition remains a continuous clinical challenge. Resveratrol has many
mechanisms of action and it could have a role in the treatment and prevention of DR [37]. In particular,
results of clinical trials on patients with type II diabetes suggest that resveratrol reduces insulin
resistance [38–41], reduces oxidative stress [39] and concentration of pro-inflammatory cytokines [42].
To our knowledge, this is the first review about resveratrol and its possible mechanisms on DR.
The aim of this study was to summarize all available literature regarding this topic. Eighteen studies
were identified.
Both in vitro [20,22] and in vivo [20,22,24,35] studies demonstrated that resveratrol may suppress
insult-induced apoptosis of retinal cells. The proposed mechanisms include microRNA-29b (miR-29b).
It might also be driven by attenuation of oxidative stress that was also shown both in vitro [23–25]
and in vivo [22,24]. Retinal superoxide dismutase activity was also shown to be elevated after
resveratrol administration.
Reduction of high glucose-induced intracellular ROS elevation could be mediated through the
activation of AMPK/Sirt1/PGC-1α pathway. Resveratrol is known as an activator of sirtuin1 (SIRT1),
one of SIRT proteins, NAD+-dependent histone/protein deacetylases. SIRTs are linked with several
signaling pathways regulating inflammation attenuation, DNA damage repair, apoptosis, redox status
and others [43]. Resveratrol was proposed to exert its anti-inflammatory and antioxidative actions as
well as suppression of tumorigenesis and vasodilation through activation of SIRT1 [9,44].
The analyzed reports also support the view that resveratrol may act through suppression
of inflammatory mechanisms. Downregulation of pro-inflammatory mediators was shown both
in vitro [24,26] and in vivo [22,24,34–36]. It is postulated that these effects might be mediated
by increased expression and activity of PON1. Another proposed mechanism is suppression of
diabetes-induced upregulation of NF-κB signaling (through AMPK pathway).
Finally, evidence of suppression of neovascularization by resveratrol is controversial. Only one
study [27] demonstrated downregulation of VEGF and a decrease in the proliferation of cultured RPE
cells. The in vivo data are not consistent. While one study [33] showed blockage of diabetes-induced
increase of VEGF expression, the other two did not find any effects of resveratrol on molecular level [32]
and on formation on new pathological vessels.
Despite the limited number of studies, there are also some other limitations of these data. Most
of the in vitro papers do not provide any data how cells/cell line misidentification was excluded;
no guidelines like [45,46] on avoiding misidentification are cited. Moreover, a large number of
animal studies we included were conducted on albino animals with compromised retinal pigment
epithelium, and most likely developing several other ocular pathologies [47,48]. Another limitation is
that resveratrol is rapidly metabolized and its biovailability is poor. Moreover, the activity of resveratrol
metabolites is not well studied.
To evaluate animal studies, we used SYRCLE’s risk of bias tool, an adapted version of Cochrane
risk of bias tool. Six out of 11 studies declare random assignment of animals to experimental groups
but none of them provide any details of the procedure. None of the studies provide any details on
blinding of the groups throughout the experiments. Only one study mentions a procedure for blinding
of the outcome assessment. No study provided calculations of sample size. Therefore, none of the
studies fully meets the current criteria of complete and transparent reporting of animal research [49].
To conclude, the results of in vitro and in vivo experiments seem to support resveratrol potential
as a candidate for clinical trials in diabetic retinopathy. In particular, activation of AMPK/Sirt1/PGC-1α
pathway could be an important mechanism mediating potential beneficial effects of resveratrol in DR.
Promising clinical data in type II diabetes patients also encourage to undertake clinical evaluation of
resveratrol potential beneficial effects in DR, even if the preclinical data specific for DR suffer from
some limitations.
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4. Materials and Methods
In this systematic review, we searched all available articles for each specific issue to explore the
effects and the mechanism of action of resveratrol on in vitro and in vivo models of DR. This review
was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [50].
A literature search of all original articles published until April 2019 was performed in parallel by
two authors (Alessandro Porta and Sarah Tripodi) using the PubMed database. The terms “resveratrol”
was searched in combination with “retina”, “retinal pathology”, “diabetic retinopathy”, “eye”. The
resulting reference lists were manually examined to identify any potential studies that were not
captured by the electronic searches.
The final list of all electronic data captured, titles and abstracts were independently examined
by two reviewers (Michele Reibaldi and Mario D. Toro) to identify relevant articles. Studies were
considered for inclusion if they included retinal changes after resveratrol administration either in
animal or in human eye with diabetic retinopathy. Then, the same reviewers registered and selected
related studies that met the above inclusion criteria by examining the full text of articles. All study
types were extracted. Reviews were excluded, but they were used to capture articles reported in
bibliography. Only English articles were included.
Any disagreement was assessed by consensus and when it was not initially reached a third
Reviewer (Michele Figus) was consulted. Two Reviewers (Michal Fiedorowicz and Chiara Posarelli)
independently extracted data using an Excel sheet.
For in vitro studies the following data were extracted: study title, author, year of publication, type
of cells and their origin, data on cell identification, resveratrol concentration, laboratory techniques
and major findings/mechanism of action. For in vivo studies: study title; author; year of publication;
animal’s species, strain, sex and age; type of animal model of diabetic retinopathy; number of animals
per group (and number of animals in total if clearly specified); route of administration and dosing of
resveratrol, laboratory techniques, tissues of interest and major findings/mechanism of action.
Quality of in vivo studies was assessed, and possible biases were identified by adopting SYRCLE’s
risk of bias tool for animal studies [51], as reported in Table 2.
Author Contributions: Conceptualization: M.D.T. and M.R.; methodology: T.A. and R.R.; validation: M.R. and
M.F.; investigation: A.P., S.T. and M.F.; software: M.F. and C.P.; data curation: M.R. and M.D.T.; writing—original
draft preparation: C.P. and M.F. (these authors equally contributed to this paper); writing—review and editing:
M.D.T.; review: K.N.; supervision: T.A. and R.R.; project administration: M.D.T. All authors gave final approval of
the submitted version.
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